UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 229

Sortiert nach

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin

Journal of experimental & clinical cancer research, 2023-01, Vol.42 (1), p.27-27, Article 27

2023

Link zum Volltext

Verfügbarkeit prüfen

Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma

Particle and fibre toxicology, 2010-03, Vol.7 (1), p.5-5

2010

Link zum Volltext

Verfügbarkeit prüfen

LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study

BMC cancer, 2023-12, Vol.23 (1), p.1206-1206, Article 1206

2023

Link zum Volltext

Verfügbarkeit prüfen

GAS5 long non-coding RNA in malignant pleural mesothelioma

Molecular cancer, 2014-05, Vol.13 (1), p.119-119, Article 119

2014

Link zum Volltext

Verfügbarkeit prüfen

BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma

Journal of cancer research and clinical oncology, 2024-01, Vol.150 (2), p.38-38, Article 38

2024

Link zum Volltext

Verfügbarkeit prüfen

Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter

BMC cancer, 2018-04, Vol.18 (1), p.475-15, Article 475

2018

Link zum Volltext

Verfügbarkeit prüfen

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

Respiratory research, 2017-04, Vol.18 (1), p.58-58, Article 58

2017

Link zum Volltext

Verfügbarkeit prüfen

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure

BMC cancer, 2019-05, Vol.19 (1), p.507-10, Article 507

2019

Link zum Volltext

Verfügbarkeit prüfen

Use of Immune Checkpoint Inhibitors in Mesothelioma

Current treatment options in oncology, 2019-02, Vol.20 (2), p.18-18, Article 18

2019

Link zum Volltext

Verfügbarkeit prüfen

The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

Cancer chemotherapy and pharmacology, 2018-01, Vol.81 (1), p.1-15

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

Molecular biology reports, 2019-06, Vol.46 (3), p.2713-2720

2019

Link zum Volltext

Verfügbarkeit prüfen

Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma

Journal of experimental & clinical cancer research, 2019-08, Vol.38 (1), p.349-349, Article 349

2019

Link zum Volltext

Verfügbarkeit prüfen

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

BMC cancer, 2012-12, Vol.12 (1), p.615-615, Article 615

2012

Link zum Volltext

Verfügbarkeit prüfen

Complexity of progranulin mechanisms of action in mesothelioma

Journal of experimental & clinical cancer research, 2022-12, Vol.41 (1), p.333-333, Article 333

2022

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism

Journal of hematology and oncology, 2017-01, Vol.10 (1), p.19-19, Article 19

2017

Link zum Volltext

Verfügbarkeit prüfen

Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies

Biochemical genetics, 2024-02, Vol.62 (1), p.352-370

2024

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray

Annals of surgical oncology, 2015-12, Vol.22 (13), p.4344-4351

2015

Link zum Volltext

Verfügbarkeit prüfen

Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment

Annals of surgical oncology, 2016-05, Vol.23 (5), p.1496-1500

2016

Link zum Volltext

Verfügbarkeit prüfen

Pifithrin-μ induces necroptosis through oxidative mitochondrial damage but accompanies epithelial–mesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis

Archives of Pharmacal Research, 2019, 42(10), , pp.890-901

2019

Link zum Volltext

Verfügbarkeit prüfen

Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms

BMC cancer, 2023-03, Vol.23 (1), p.287-287, Article 287

2023

Link zum Volltext

Verfügbarkeit prüfen

Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma

Investigational new drugs, 2021-06, Vol.39 (3), p.644-657

2021

Link zum Volltext

Verfügbarkeit prüfen

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification

Journal of translational medicine, 2018-10, Vol.16 (1), p.282-15, Article 282

2018

Link zum Volltext

Verfügbarkeit prüfen

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

Investigational new drugs, 2018-04, Vol.36 (2), p.217-229

2018

Link zum Volltext

Verfügbarkeit prüfen

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

BMC cancer, 2013-04, Vol.13 (1), p.205-205, Article 205

2013

Link zum Volltext

Verfügbarkeit prüfen

The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak

Molecular cancer, 2013-05, Vol.12 (1), p.42-42, Article 42

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 229

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

KollektionSpringerLink (Online service)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(223)

Publikationsform

Artikel
(229)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin

Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma

LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study

GAS5 long non-coding RNA in malignant pleural mesothelioma

BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma

Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure

Use of Immune Checkpoint Inhibitors in Mesothelioma

The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

Complexity of progranulin mechanisms of action in mesothelioma

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism

Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies

Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray

Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment

Pifithrin-μ induces necroptosis through oxidative mitochondrial damage but accompanies epithelial–mesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis

Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms

Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak

Aktive Filter

Suchergebnisse filtern